In this interview, Mark Levis, MD, PhD, of the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, speaks about TP53-mutated myelodysplastic syndromes (MDS) and the results of the Phase Ib/II clinical trial (NCT03072043) headed by the MDS Clinical Research Consortium, which showed promising response rates for the treatment of this condition with the mutant p53 activator APR-246 when given in combination with azacitidine. This interview was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.
